期刊文献+

羟氯喹增加胰岛素抵抗大鼠模型胰岛素敏感性的实验研究 被引量:7

Experimental study on hydroxychloroquine raised insulin sensitivity in insulin resistance rat models
下载PDF
导出
摘要 目的 :观察羟氯喹对高脂饮食大鼠胰岛素敏感性的影响。方法 :高脂大鼠灌服羟氯喹后用正常葡萄糖钳夹试验测定胰岛素敏感性 (GIR6 0 - 12 0 ) ,并测量血糖、血脂和胰岛素等。结果 :(1)高脂喂养 4周 ,大鼠的空腹血糖、胰岛素、血脂、体重均显著增高 ,胰岛素敏感性下降。 (2 )服用羟氯喹、罗格列酮和二甲双胍 2周后 ,高脂大鼠的胰岛素敏感性显著改善 ,GIR6 0 -12 0值分别为 9.3± 1.2、11.6± 1.4、9.8± 1.3、mg·kg - 1min - 1,服用羟氯喹大鼠的血糖、血脂显著低于服安慰剂的高脂大鼠。结论 :(1)高脂喂养法成功地制备了胰岛素抵抗大鼠模型。 (2 )羟氯喹能增加胰岛素敏感性 ,其作用与二甲双胍相似 ,但不及罗格列酮 ;羟氯喹对血糖。 Objective:To observe the effects of hydroxychloroquine on insulin sensitivity in high-fat feeding rats.Methods:After administrating hydroxychloroquine,the glucose infusion rate (GIR) determined by euglycemic clamp was used to measure the insulin sensitivity,and determining fasting plasma glucose,lipid and insulin.Results:(1)In high-fat feeding rats,the GIR60-120 was lower and the fasting plasma glucose,insulin,lipid levels were higher than those in normal feeding rats.(2)Hydroxychloroquine,rosiglitazone and metformin increased insulin sensitivity (the value of GIR60-120 was 9.3±1.2,11.6±1.4 and 9.8±1.3 mg.kg/min,respectively) in insulin resistance (IR) models.Moreover,the fasting glucose and some plasma lipid indices were improved in the IR rats with hydroxychloroquine administration.Conclusion:It is indicated that hydroxychloroquine could raise insulin sensitivity of IR rats with high-fat feeding,which was similar to metfomin but lower than rosiglitazone.In addition,hydroxychloroquine also could improve the glucose and blood lipid of the IR rats in some extent.
出处 《重庆医科大学学报》 CAS CSCD 2004年第4期429-432,共4页 Journal of Chongqing Medical University
基金 重庆市卫生局资助 ( 0 0 -2 0 3 2 )
关键词 羟氯喹 罗格列酮 二甲双胍 胰岛素敏感性 胰岛素抵抗 Hydroxychloroquine Rosiglitazone Metformin Insulin sensitivity Insulin resistance
  • 相关文献

参考文献11

  • 1李晨钟,张素华,舒昌达,任伟.用高脂肪膳食复制胰岛素抵抗大鼠模型[J].基础医学与临床,2000,20(3):93-95. 被引量:45
  • 2Pederson O, Kahn CR, Flier JS, et al. High fat feeding cause insulin resistance and a marked decrease in the expression of glucose transporters ( Glut - 4) in fat cells of rats [J]. Endocrinology, 1991; 129: 771 - 777.
  • 3Emani J, Pasutto FM, Mercer JR, et al. Inhibition of insulin of metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats[J]. Life Sci, 1999;64(5) :325 - 35.
  • 4Bailey CJ,Turner RC. Metformin[J]. N Enl J Med.1996;334(9) :574 - 579.
  • 5Saltiel AR, Olefsky J. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes[J]. Diabetes.1996;45(12): 1661 - 1669.
  • 6Petri M. Hydroxychloroquine used in the Baltimore Lupus Cohort: effects on lipids glucose and thrombosis [J]. Lupus,1996;5(1) :S16 - 22.
  • 7Powrie JK, Smith GD, Shojaee - Moradie F, et al. Mode of action of chloroquine in patients with non - insulin - dependent diabetes mellitus [J]. Am J Physiol, 1991; 260 ( 6 Pt 1 ):E897 - 904.
  • 8Quatraro A,Consoli G,Magno M,et al. Hydroxychloroquine in Decompensated, Treatment - Refractory NoninsulinDependent Diabetes Mellitus[J]. Ann Intern Med, 1990; 112(9) :678 - 681.
  • 9Storlien LH,Oakes ND, Pan D, et al. Syndromes of insulin resistance in the rat. Inducement by diet and the amelioration with benfluorex[J]. Diabetes, 1993 ;42:457 - 460.
  • 10J eppsen J ,Zhou MY, Chen YD, et al. Effect of metformin on postprandial lipidemia in patients with fairly to peorly controlled NIDDM[J]. Diabetes care. 1994; 17(10): 1093 - 1099.

二级参考文献1

共引文献44

同被引文献58

  • 1Ioachimescu AG,Brennan DM,Hoar BM,et al.Serum uric acid is an independent predictor of all cause mortality in patients at high risk of cardiovascular disease:a preventive cardiology information system (PrdCIS) database cohort study[J].Arthritis Rheum,2008,58:623-630.
  • 2Choi HK,De Vera MA,Krishnan E.Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile[J].Rheumatology(Oxford),2008,47:1567-1570.
  • 3Rahman P,Gladman DD,Urowitz MB,et a1.The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs[J].Rheumatol,1999,26(2):325-330.
  • 4Costedoat Chalumeau N,Leroux G,Piette JC,et a1.Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment[J].Joint Bone Spine,2010,77(1):4-5.
  • 5Costedoat Chalumeau N,Amoura Z,Hulot J.et a1.Hydroxychloroquine in systemic lupus erythematosus[J].Lancet,2007,369(9569):1257-1258.
  • 6Costedoat-Chalumeau N,Leroux G,Piette JC,et al.Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment[J].Joint Bone Spine,2010,77(1):4-5.
  • 7Rahman P,Gladman DD,Urowitz MB,et 1a.The cholesterol loweirng effect ofantimalarila durg sisenhanced in patientswithlupus taking corticosteroid durgs[J].Rheumatol,1999,26(2):325-330.
  • 8Elder M,Rahman AM,McLay J.Early paracentral visualfield loss inpatients taking hydroxychloroquine[J].ArchOphthalmol,2006,124(12):1729-1733.
  • 9Ioachimescu AG,Brennan DM,Hoar BM,et al.Serum uric acid is an independent predictor of all cause mortality in patients at high risk of cardiovascular disease:a preventive cardiology information system (PrdCIS) database cohort study[J].Arthritis Rheum,2008,58(2):623-630.
  • 10Choi HK,De Vera MA,Krishnan E.Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile[J].Rheumatology(Oxford),2008,47(10):1567-1570.

引证文献7

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部